Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study.
The Lancet Haematology.
Times cited: 1
- Central nervous system involvement by multiple myeloma: A multi-institutional retrospective study of 172 patients in daily clinical practice. American journal of hematology. 2016 Academic Article GET IT
Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report.
Times cited: 79
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma.
The Lancet. Oncology.
Times cited: 354
- New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG). Leukemia. 2014 Information Resource GET IT